

Title

In-hospital Outcomes of Acute Ischemic Stroke in Atrial Fibrillation Patients on Anticoagulation: A Retrospective Analysis

Authors

Moises A Vasquez MD^{1#}, MD1, Litsa K. Lambrakos MD², Alex Velasquez MD², Jeffrey J. Goldberger MD, MBA², Raul D. Mitrani, MD, FHRS, CCDS²

Affiliations

1 Department of Internal Medicine, University of Miami Miller School of Medicine/Jackson Memorial Hospital, Miami, Florida, USA

2 Department of Medicine, Department of Cardiovascular Diseases, University of Miami Miller School of Medicine, Miami, FL

#Corresponding author:

Email: mav256@med.miami.edu

Address: 1611 NW 12th Ave, C-600D, Miami, FL 33136

Department of Internal Medicine, University of Miami Miller School of Medicine/Jackson Memorial Hospital, Miami, Florida, USA

Authors declare no conflict of interest.

Running title: Stroke outcomes in atrial fibrillation on anticoagulation

Word count: 4,928

ABSTRACT

Background. Long-term anticoagulation (AC) therapy reduces the risk of stroke in patients with Atrial Fibrillation (AF). Data on the impact of AC on in-hospital stroke outcomes is lacking.

Methods. The National Inpatient Sample was used to identify adult inpatients with AF and a primary diagnosis of ischemic stroke between 2016 and 2020. Data was stratified between patients on AC users and nonusers. A multivariate regression model was used to describe the in-hospital outcomes, adjusting for significant comorbidities.

Results A total of 655,540 patients with AF and a diagnosis of ischemic stroke were included, of which 194,560 (29.7%) were on long-term AC. Patients on AC tended to be younger (mean age, 77 vs 78), had a higher average CHA₂DS₂-VASc score (4.48 vs 4.20), higher rates of hypertension (91% vs 88%), hyperlipidemia (64% vs 59%), and heart failure (34% vs 30%) compared to patients not on long-term AC. Use of AC was associated with decreased in-hospital mortality (aOR [95% CI]: 0.62 [0.60 - 0.63]), decreased stroke severity (mean NIHSS, 8 vs 10), decreased use of tPA (aOR 0.42 [0.41 - 0.43]), mechanical thrombectomy (aOR 0.85 [0.83 - 0.87]), hemorrhagic conversion (aOR 0.69 [0.67 - 0.70]), gastrointestinal bleeding (aOR 0.74 [0.70 - 0.77]), and discharge to skilled nursing facilities (aOR 0.90 [0.89 - 0.91]), compared to patients not on AC (P<0.001 for all comparisons).

Conclusion. Among patients with AF admitted with acute ischemic stroke, AC use prior to stroke was associated with decreased in-hospital mortality, decreased stroke severity, decreased discharge to SNF, and fewer stroke-related and bleeding complications.

Abbreviations: AF: Atrial Fibrillation; NVAf: Nonvalvular Atrial Fibrillation; AC: Anticoagulation; DOAC: direct oral anticoagulants; VKA: vitamin K antagonists; LAAC: Left Atrial Appendage Closure; IS: Ischemic Stroke; SEE: Systemic Embolic Events; TIA: Transient Ischemic Attack; NIS: National Inpatient Sample.

Introduction

Atrial Fibrillation (AF) is associated with an increased risk of ischemic stroke, systemic embolism, and death (1). In the USA, about 10%–12% (~80000) of ischemic strokes occur in the setting of AF and carry higher morbidity and mortality than those occurring in patients without AF (2). Oral anticoagulation (AC) with direct oral anticoagulants (DOACs) or vitamin K antagonists (VKA) have shown to substantially reduce the risk of stroke. Nevertheless, despite these advancements in stroke prevention, strokes in patients with AF continue to be a significant burden. Recent studies show that 22% to 36% of ischemic strokes in patients with AF occur while on anticoagulation(3,4). Furthermore, patients with AF that have had a prior stroke are at a higher risk of stroke recurrence, even while on AC (3,4).

Although the effect of oral anticoagulants on the frequency of stroke is clear, its impact on the severity of stroke and stroke-related inpatient outcomes among patients with AF has been less well studied, particularly in the DOAC era. Previous studies from the VKA era suggest that strokes happening while on anticoagulation may not have as severe short and long-term clinical outcomes (5–9). Few other studies in the DOAC era have shown similar outcomes (9–13). However, contemporary data on the inpatient outcomes of acute ischemic stroke among anticoagulated patients with AF in the United States in the DOAC era is scarce. Therefore, we set to use a nationwide, representative database to compare the inpatient outcomes of acute ischemic stroke among patients with AF on long-term AC compared to nonusers in the US.

Methods

Study Data

We utilized a retrospective study using the National Inpatient Sample (NIS) database. This database is the largest source of inpatient care data in the United States, compiled from billing information provided by hospitals to state data organizations as part of the Healthcare Cost and Utilization Project (HCUP). It includes over 100 clinical data elements from over 7 million unweighted hospital admissions annually, representing 20% of all U.S. hospital admissions. We applied a standardized sampling and weighting methodology, as provided by the HCUP, to make national estimates for the entire hospitalized population in the U.S. The NIS database is widely used for assessing inpatient outcomes in various conditions and procedures, including AF and ischemic stroke (14–16).

The study was exempted from institutional review board approval due to the use of a deidentified administrative database. We strictly followed the NIS survey methodology for data interpretation, research design, and analysis, in accordance with HCUP guidelines. The study also conformed to the Strengthening the Reporting of Observational Studies in Epidemiology Statement guidelines and incorporated best practice methodologies for using claims datasets.

Study Population and Outcomes

We identified hospitalizations with primary diagnosis codes for acute ischemic stroke and secondary diagnosis codes for AF from 2016 to 2020, based on the *International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10)* codes.

Inclusions were stratified by patients on long-term AC. All utilized ICD-10 diagnosis and procedure codes are listed in Supplementary Table 1.

For each hospitalization, we collected data on patient demographics, clinical characteristics, and hospital characteristics. Demographic variables included were age, sex, and race/ethnicity. Hospital characteristics included location/teaching status (rural, urban nonteaching, or urban teaching) and hospital bed size (small, medium, or large), while clinical characteristics covered relevant co-morbidities. The ICD-10-CM codes used for these variables have been previously validated and are consistent with prior publications (14–17) .

The primary outcome of interest was all-cause in-hospital mortality. Secondary outcomes included stroke severity by National Institutes of Health Stroke Scale (NIHSS), intravenous thrombolysis and mechanical thrombectomy rates, in-hospital bleeding complications, hospital length of stay (LOS), total hospital costs, and discharge disposition. Patients with an NIHSS score of 1 to 4 were categorized as mild, 5-15 as moderate; 16 to 20 as moderate to severe, and above 21 as severe (18). The corresponding ICD-10 codes for each in-hospital outcome were identified using the same method as for co-morbidity codes.

Statistical Analysis

We compared categorical variables using the Pearson Chi-Squared test and continuous variables using the Student t-test for normally distributed data, and the Mann-Whitney U test for non-normally distributed data. Categorical data were presented as counts and percentages, and continuous data were expressed as median with interquartile ranges (IQRs).

Multivariate analysis provided adjusted odds ratios (aORs) for binary variables, controlling for age, sex, and significant comorbidities. Associations were expressed through aORs with 95% confidence intervals (CI). The variables for adjustment in the multivariate regression model were chosen in advance based on their potential impact on in-hospital outcomes (see Supplementary Table 3). Statistical significance was set at $p < 0.05$. All analyses were performed using SPSS (IBM SPSS Statistics, Version 28.0). Weighted data were utilized for all statistical analyses, and missing demographic data were addressed through multiple imputation to the dominant category as recommended by the HCUP.

Results

A total of 655,540 patients with AF hospitalized with a primary diagnosis of acute ischemic stroke were identified between 2016 and 2020. Of these, 194,560 (29.7%) were on long-term AC (**Figure 1**). AC users tended to be slightly younger (mean age \pm SD, 77 ± 10 vs. 78 ± 11 years; $p < 0.001$), predominantly female (50.5% vs. 54.2%; $p < 0.001$), and more frequently White (77.5% vs. 76.9%; $p < 0.001$). They were also more likely to have persistent (4.5% vs 3.6%, $p < 0.001$) and permanent AF (31.9% vs 17.8%, $p < 0.001$) compared to AF patients not on AC. On the other hand, AC nonusers were more likely to have paroxysmal AF (36.2% vs 29.7%, $p < 0.001$). Patients on AC had a higher mean CHA₂DS₂-VASc score (mean \pm SD, 4.48 ± 1.6 vs 4.20 ± 1.6 , $p < 0.001$), and a higher proportion of patients with a CHA₂DS₂-VASc score between 5 and 9 (48.1% vs 41.2%, $p < 0.001$). Patients on AC were less likely to be admitted to large (53.9% vs 55.2%, $p < 0.001$), urban teaching hospitals (71.9% vs 74.0%, $p < 0.001$) compared to patients not on AC. AF Patients on previous AC had a higher baseline comorbidity burden such as

hyperlipidemia (64.3% vs 58.9%, $p < 0.001$), hypertension (90.8% vs. 88.2%; $p < 0.001$), diabetes mellitus (37.4%, vs. 35.1%; $p < 0.001$), heart failure (33.8% vs. 29.9%; $p < 0.001$), chronic kidney disease (24.0% vs. 23.5%; $p < 0.001$), and coronary artery disease (36.2% vs. 32.1%; $p < 0.001$), and were more likely to have had a previous stroke or TIA (35.1% vs 24.6%, $p < 0.001$) compared to AF patients not on AC. The baseline characteristics are listed in **Table 1**.

While the majority of strokes were unclassified (**Table 3**), a lower percent of strokes in patients on AC was attributed to embolic source, compared to patients not on AC (30.6% vs 33.7%, $p < 0.001$). Vessels occluded in AC users were less often large vessels such as the middle cerebral (30.0% vs 36.0%, $p < 0.001$), anterior cerebral (2.0% vs 2.2%, $p < 0.001$), or posterior cerebral arteries (4.9% vs 5.4%, $p < 0.001$) compared to nonusers. Furthermore, patients on AC often had small vessel occlusion (2.7% vs 1.7%, $p < 0.001$) compared to patients not on AC. Median NIHSS score among AC users was lower (5 [2 – 12] vs 7 [2 – 16], $p < 0.001$). They also had a higher proportion of strokes categorized as mild (NIHSS score ≤ 4) compared to nonusers (19.5% vs 15.4%, $p < 0.001$), and less frequently underwent revascularization with intravenous thrombolysis (7.3% vs 16.6%, $p < 0.001$) or mechanical thrombectomy (7.1% vs 8.9%, $p < 0.001$).

Unadjusted in-hospital mortality rates among AF patients on long-term AC were significantly lower compared to those not on AC (4.8% vs 7.8%, $p < 0.001$). Bleeding complications such as intracranial hemorrhage (ICH) (6.4% vs 9.2%, $p < 0.001$) and Gastrointestinal (GI) bleeding events (1.5% vs 2.1%, $p < 0.001$) were also significantly lower in AF patients on previous AC. Moreover, AC users had a shorter hospital LOS (median, [IQR] ; 4 [3 – 7]vs 4 [2 – 6]; $p <$

0.001), and lower average total costs (median USD [IQR]; \$48,130 [\$27,089 - \$91,45] vs \$40,135 [\$24,130 - \$74,378]; $p < 0.001$) compared to nonusers. AF patient on previous AC were discharged at lower rates to a skilled nursing facility (SNF) or intermediate care facility (48.1% vs 50.5%; $p < 0.001$) and discharged at greater rates to home (25.8% vs 22.5%; $p < 0.001$) compared to those not on AC.

After adjusting for potential confounders using a multivariate logistic regression, long-term AC use was associated with decreased odds of in-hospital mortality (aOR [95% CI]: 0.62 [0.60 - 0.63], $p < 0.001$), intravenous thrombolysis use (0.42 [0.41 - 0.43], $p < 0.001$), mechanical thrombectomy use (0.85 [0.83 - 0.87], $p < 0.001$), ICH (0.69 [0.67 - 0.70], $p < 0.001$), GI bleed (0.74 [0.70 - 0.77], $p < 0.001$), and all major bleeding events (0.73 [0.71 - 0.74], $p < 0.001$).

Adjusted odds of routine discharge were significantly higher for patients on long-term AC (1.26 [1.24 - 1.28], $p < 0.001$), while the odds of discharge to SNF or other type of intermediate care facility were lower (0.90 [0.89 - 0.91], $p < 0.001$). Forest plot showing odd ratios of the unadjusted and adjusted analyses is shown in **Figure 2**.

Discussion

In this study, we present several significant findings. Only 29.7% of AF patients who experienced an acute ischemic stroke were receiving long-term anticoagulation at the time of the event despite the availability of the newer direct acting oral anticoagulant drugs. Importantly, patients on anticoagulation had lower in-hospital mortality rate and reduced stroke severity. These strokes were less likely to involve major blood vessels and resulted in fewer discharges to

skilled nursing facilities. Moreover, these patients had fewer chemical or mechanical thrombectomy procedures, and paradoxically, experienced fewer bleeding complications during their hospital stay.

Our data indicate that on third of AF patients were anticoagulated at the stroke onset, consistent with previous research (4,12,19,20). These patients typically had more comorbidities and higher average CHADS₂VAS₂C scores compared to those not on AC. Uncontrolled comorbidities, hyperlipidemia, high CHA₂DS₂VASc scores, and atherosclerosis have been identified as important risk factors for strokes despite AC therapy in AF patients (3,21). The more advanced AF disease process would likely have brought these patients to healthcare allowing more opportunity for providers to initiate guideline directed anticoagulation therapy. However, other factors such as increased AF burden (a sign of more advanced cardiac disease), insufficient anticoagulation (off label use of low dose DOAC or subtherapeutic VKA), or non-compliance are particularly influential in embolic breakthrough strokes (3,21,22). This aligns with our findings of a higher AF burden and medication non-compliance in those on previous AC.

The number of patients not on anticoagulants who might have previously undergone left atrial appendage occlusion (LAAO) in our sample is uncertain. However, as percutaneous LAAO was a relatively uncommon procedure during our study period, the relative number of patients who may have had prior LAAO, and thus benefit from embolic stroke prevention, is likely to be small. For patients where high bleeding risk is a concern and AC is contraindicated, LAAO could be beneficial. Among those not on AC, over 95% had a high-risk for stroke (CHADS₂VAS₂C \geq 2) but were not reported to be on long-term AC. These findings indicate that

a significant portion of strokes in AF patients may be attributable to insufficient or underutilized anticoagulation therapy. This highlights a potential avenue for reducing stroke rates among individuals with AF.

Using the large sample size from the NIS, this study demonstrated decreased stroke-associated in-hospital mortality and decreased stroke severity by NIHSS score in previously anticoagulated AF patients compared to those not on AC. Past multicenter studies have established that prior therapeutic warfarin treatment lessens stroke severity (5–9). A retrospective study by Hylek et al., initially revealed an association between successful anticoagulation and a decrease in disability as well as mortality within 30 days following an ischemic stroke (5). Comparable findings were observed in in-hospital data collected from a registry encompassing 11 hospitals in Canada (6). Studies also indicate that prior DOAC treatment lowers stroke severity and improves short-term outcomes, (9–13). A study spanning 2012 to 2015 demonstrated that therapeutic anticoagulation with warfarin or DOACs correlated with lower chances of moderate or severe stroke and reduced in-hospital mortality, which is in line with our findings (9). Another cohort reported that prior DOAC treatment was associated with lower risk of severe neurological deficit (NIHSS score ≥ 11) and death or disability (mRS score ≥ 3) at discharge in ischemic stroke patients with atrial fibrillation (11). Reported median NIHSS scores range from 4 to 8 for AF patients on therapeutic anticoagulation, versus 7 to 11 for those not on anticoagulation or on non-therapeutic doses, matching our results (9,12,13). These prior studies had smaller samples or focused mostly on functional short and long-term outcomes. To our knowledge, the present study has the largest sample size to examine contemporary, in-hospital outcomes in AF patients on previous AC admitted for acute ischemic stroke in the DOAC era.

The diminished stroke severity observed in patients on anticoagulation likely reflects smaller thrombus size, and thus decreased LVO and infarct volume (7,13,23–25). Decreased frequency of embolic strokes, which characteristically have a higher affinity for the total anterior circulation and often result in more severe strokes, is also thought to play a role (23–25). The literature is inconsistent regarding the predominant stroke etiology between embolic or non-embolic in AF patients that suffer strokes while on anticoagulation. In this study, embolic etiology was a primary mechanism for stroke. (12,22,26). Nevertheless, we observed lower involvement of total anterior circulation vessels (anterior and middle cerebral arteries), more small vessel circulation strokes, and fewer total embolisms in the anticoagulated group compared to those not on anticoagulation, indicating effective anticoagulation might lead to smaller embolus size and thus occlusion of smaller arteries (7,13,23–25).

In comparison to VKA, DOACs have a shorter half-life (6–14 hours) and a rapid onset of action (27). Current major stroke guidelines advise against routine intravenous thrombolysis within 48 hours of DOAC intake unless specific DOAC coagulation assays are normal (28,29). Many patients on DOACs, despite being eligible, do not receive intravenous thrombolysis due to the risk of hemorrhagic transformation (3,4,25). Similarly, we noted lower rates of intravenous thrombolysis in our observations. Mechanical thrombectomy rates were also lower among patients on AC. This differs from prior studies reporting increased rates of mechanical thrombectomy in this population as a reperfusion strategy since of intravenous thrombolysis is usually avoided (3,4,20,25). As guidelines recommend mechanical thrombectomy particularly in the setting of acute ischemic stroke and concomitant LVO (29), perhaps as anticoagulated patients presented with LVO less frequently, they required mechanical thrombectomy less often.

Limitations

There are several limitations to this study. Data collected from the NIS database is primarily compiled based on ICD codes, which represent “claims data” for reimbursement purposes and for summarizing clinical presentations in retrospect. Thus, patient level data is not available, such as time from stroke onset to initial medical care, contraindications to IS treatments, or neuroimaging data. There could be unmeasured and unknown confounding factors that are not captured in the NIS database, such as patient preference and provider-level rationale, that are important determinants of clinical decisions and may in part account for observed associations. We did not have data as to how many patients presented with newly diagnosed AF which is another confounder. As with all administrative datasets, misclassification bias is a limitation, although our use of previously validated ICD-10-CM codes for stroke in the primary discharge diagnosis position limits that bias for the identification of patients. It is more likely that we under captured patients under long-term AC, because of lack of documentation. When looking at stroke severity, 60.2% had missing NIHSS score. Since every observation represents a hospitalization, information before or after the hospital admission is not available, such as timing from stroke to admission, or 30-day outcomes. We also lack granularity in many of our variables due to the administrative nature of NIS. For example, information on the specific anticoagulant patients were taking or INR levels on admission (if on warfarin), and further ischemic stroke type classification are not available.

Conclusion

In summary, using a large, nationwide database, this study supports a compelling argument that anticoagulation reduces stroke severity and stroke associated disability for those who have strokes despite anticoagulation. In particular, we observed that AC use in AF patients prior to stroke was associated with lower in-hospital mortality, lower stroke severity, and lower bleeding complications compared to patients not on AC. These patients had a shorter LOS and were less likely to be discharged to a SNF or ICF.

Disclosures

The authors declare no conflict of interest.

References

1. Yaghi S, Kamel H. Stratifying Stroke Risk in Atrial Fibrillation: Beyond Clinical Risk Scores. *Stroke*. 2017;48(10):2665-2670. doi:10.1161/STROKEAHA.117.017084
2. Ali AN, Abdelhafiz A. Clinical and Economic Implications of AF Related Stroke. *J Atr Fibrillation*. 2016;8(5):1279. doi:10.4022/jafib.1279
3. Stretz C, Wu TY, Wilson D, et al. Ischaemic stroke in anticoagulated patients with atrial fibrillation. *J Neurol Neurosurg Psychiatry*. 2021;92(11):1164-1172. doi:10.1136/jnnp-2020-323963
4. Seiffge DJ, De Marchis GM, Koga M, et al. Ischemic Stroke despite Oral Anticoagulant Therapy in Patients with Atrial Fibrillation. *Ann Neurol*. 2020;87(5):677-687. doi:10.1002/ana.25700
5. Hylek EM, Go AS, Chang Y, et al. Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation. *N Engl J Med*. 2003;349(11):1019-1026. doi:10.1056/NEJMoa022913
6. O'Donnell M, Oczkowski W, Fang J, et al. Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study. *Lancet Neurol*. 2006;5(9):749-754. doi:10.1016/S1474-4422(06)70536-1

7. Schwammenthal Y, Bornstein N, Schwammenthal E, et al. Relation of Effective Anticoagulation in Patients With Atrial Fibrillation to Stroke Severity and Survival (from the National Acute Stroke Israeli Survey [NASIS]). *Am J Cardiol*. 2010;105(3):411-416. doi:10.1016/j.amjcard.2009.09.050
8. Myint PK, Hellkamp AS, Fonarow GC, et al. Prior Antithrombotic Use Is Associated With Favorable Mortality and Functional Outcomes in Acute Ischemic Stroke. *Stroke*. 2016;47(8):2066-2074. doi:10.1161/STROKEAHA.115.012414
9. Xian Y, O'Brien EC, Liang L, et al. Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation. *JAMA*. 2017;317(10):1057-1067. doi:10.1001/jama.2017.1371
10. Tomita H, Hagii J, Metoki N, et al. Severity and Functional Outcome of Patients with Cardioembolic Stroke Occurring during Non-vitamin K Antagonist Oral Anticoagulant Treatment. *J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc*. 2015;24(6):1430-1437. doi:10.1016/j.jstrokecerebrovasdis.2015.03.004
11. Hellwig S, Grittner U, Audebert H, Endres M, Haeusler KG. Non-vitamin K-dependent oral anticoagulants have a positive impact on ischaemic stroke severity in patients with atrial fibrillation. *Europace*. 2018;20(4):569-574. doi:10.1093/europace/eux087
12. Sakamoto Y, Okubo S, Nito C, et al. The relationship between stroke severity and prior direct oral anticoagulant therapy in patients with acute ischaemic stroke and non-valvular atrial fibrillation. *Eur J Neurol*. 2017;24(11):1399-1406. doi:10.1111/ene.13405
13. Tokunaga K, Koga M, Itabashi R, et al. Prior Anticoagulation and Short- or Long-Term Clinical Outcomes in Ischemic Stroke or Transient Ischemic Attack Patients With Nonvalvular Atrial Fibrillation. *J Am Heart Assoc*. 2019;8(3):e010593. doi:10.1161/JAHA.118.010593
14. Havenon A de, Sheth K, Johnston KC, et al. Acute Ischemic Stroke Interventions in the United States and Racial, Socioeconomic, and Geographic Disparities. *Neurology*. 2021;97(23):e2292-e2303. doi:10.1212/WNL.0000000000012943
15. Alkhouli M, Alqahtani F, Aljohani S, Alvi M, Holmes DR. Burden of Atrial Fibrillation–Associated Ischemic Stroke in the United States. *JACC Clin Electrophysiol*. 2018;4(5):618-625. doi:10.1016/j.jacep.2018.02.021
16. Aggarwal G, Patlolla SH, Aggarwal S, et al. Temporal Trends, Predictors, and Outcomes of Acute Ischemic Stroke in Acute Myocardial Infarction in the United States. *J Am Heart Assoc*. 2021;10(2):e017693. doi:10.1161/JAHA.120.017693
17. Vasquez MA, Iskander M, Mustafa M, et al. Pericardiocentesis Outcomes in Patients With Pulmonary Hypertension: A Nationwide Analysis from the United States. *Am J Cardiol*. 2023;210:232-240. doi:10.1016/j.amjcard.2023.10.047

18. Adams HP, Davis PH, Leira EC, et al. Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). *Neurology*. 1999;53(1):126-131. doi:10.1212/wnl.53.1.126
19. Yaghi S, Henninger N, Giles JA, et al. Ischaemic stroke on anticoagulation therapy and early recurrence in acute cardioembolic stroke: the IAC study. *J Neurol Neurosurg Psychiatry*. 2021;92(10):1062-1067. doi:10.1136/jnnp-2021-326166
20. D'Anna L, Filippidis FT, Harvey K, Korompoki E. Ischemic stroke in oral anticoagulated patients with atrial fibrillation. *Acta Neurol Scand*. 2022;145(3):288-296. doi:10.1111/ane.13552
21. Paciaroni M, Agnelli G, Caso V, et al. Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. *Stroke*. 2019;50(8):2168-2174. doi:10.1161/STROKEAHA.119.025350
22. Purruicker JC, Hölscher K, Kollmer J, Ringleb PA. Etiology of Ischemic Strokes of Patients with Atrial Fibrillation and Therapy with Anticoagulants. *J Clin Med*. 2020;9(9):2938. doi:10.3390/jcm9092938
23. Hart RG, Pearce LA, Miller VT, et al. Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies. *Cerebrovasc Dis Basel Switz*. 2000;10(1):39-43. doi:10.1159/000016023
24. Longstreth WT, Bernick C, Fitzpatrick A, et al. Frequency and predictors of stroke death in 5,888 participants in the Cardiovascular Health Study. *Neurology*. 2001;56(3):368-375. doi:10.1212/wnl.56.3.368
25. Meinel TR, Branca M, De Marchis GM, et al. Prior Anticoagulation in Patients with Ischemic Stroke and Atrial Fibrillation. *Ann Neurol*. 2021;89(1):42-53. doi:10.1002/ana.25917
26. Hayashi T, Kato Y, Fukuoka T, et al. Clinical Features of Ischemic Stroke during Treatment with Dabigatran: An Association between Decreased Severity and a Favorable Prognosis. *Intern Med*. 2015;54(19):2433-2437. doi:10.2169/internalmedicine.54.4948
27. Gosselin RC, Adcock DM, Bates SM, et al. International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. *Thromb Haemost*. 2018;118(3):437-450. doi:10.1055/s-0038-1627480
28. Berge E, Whiteley W, Audebert H, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. *Eur Stroke J*. 2021;6(1):I-LXII. doi:10.1177/2396987321989865
29. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early

Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke*. 2019;50(12):e344-e418. doi:10.1161/STR.0000000000000211

Table 1. Baseline characteristics in patients undergoing pericardiocentesis, with and without pulmonary hypertension.

	No Anticoagulation, n=460,980 (%)	Anticoagulation, n=194,560 (%)	P
Age, years [IQR]	80 [71- 87]	79 [71 - 86]	< 0.001
Female	249,720 (54.2)	98,345 (50.5)	< 0.001
Race			
White	343,670 (76.9)	146,480 (77.5)	< 0.001
Black	46,745 (10.5)	20,285 (10.7)	
Hispanic	30,030 (6.7)	12,215 (6.5)	
Other Races	26,435 (6.0)	10,052 (5.4)	
Atrial Fibrillation type			
Paroxysmal	166,855 (36.2)	57,735 (29.7)	<0.001
Persistent	16,630 (3.6)	8,815 (4.5)	
Permanent	82,275 (17.8)	62,035 (31.9)	
Unspecified	195,220 (42.3)	65,975 (33.9)	
Mean CHADSVASc ±SD	4.20 ±1.57	4.48 ± 1.56	<0.001
CHADSVASc 0 - 1	20,920 (4.5)	4,875 (2.5)	
CHADSVASc 2 - 4	250,240 (54.3)	96,005 (49.3)	
CHADSVASc 5 - 9	189,820 (41.2)	93,680 (48.1)	
Hospital Characteristics			
Relative bed size category of hospital			
Small	74,800 (16.2)	33,810 (17.4)	< 0.001
Medium	131,905 (28.6)	55,950 (28.8)	
Large	254,275 (55.2)	104,800 (53.9)	
Location/teaching status of hospital			
Rural	31,795 (6.9)	15,360 (7.9)	< 0.001
Urban nonteaching	88,005 (19.1)	39,375 (20.2)	
Urban teaching	341,180 (74.0)	139,825 (71.9)	
Hospital Region			
Northeast	87,700 (19.0)	36,295 (18.7)	< 0.001
Midwest	98,130 (21.3)	47,120 (24.2)	
South	181,465 (39.4)	72,840 (37.4)	
West	93,685 (20.3)	38,305 (19.7)	
Comorbidities			
Coagulopathy	9,255 (2.0)	5,845 (3.0)	<0.001
Hypertension	406,525 (88.2)	176,625 (90.8)	<0.001
Hyperlipidemia	271,480 (58.9)	125,115 (64.3)	<0.001
Diabetes	160,385 (35.1)	72,140 (37.4)	<0.001
Hypothyroidism	86,105 (19.0)	37,480 (19.5)	<0.001
Obesity	59,500 (12.9)	26,750 (13.7)	<0.001
Tobacco use	140,805 (30.5)	70,325 (36.1)	<0.001
Alcohol use	15,960 (3.5)	4,915 (2.5)	<0.001

Chronic lung disease	83,575 (18.1)	37,180 (19.1)	<0.001
Chronic liver disease	11,165 (2.4)	3,760 (1.9)	<0.001
CKD	107,675 (23.5)	46,585 (24.0)	<0.001
Dialysis dependent	6,665 (1.4)	3,040 (1.6)	<0.001
Anemia	72,870 (15.8)	27,475 (14.1)	<0.001
CAD	147,915 (32.1)	70,430 (36.2)	<0.001
Heart Failure	137,830 (29.9)	65,845 (33.8)	<0.001
Peripheral vascular disease	42,810 (9.3)	17,830 (9.2)	0.118
Valve disease	9,245 (2.0)	11,855 (6.1)	
Malignancy	22,965 (5.0)	10,095 (5.2)	<0.001
Previous History			
History of MI	540,035 (8.7)	19,545 (10.0)	0.125
History of TIA/Stroke	113,135 (24.6)	68,315 (35.1)	< 0.001
History of Medication Noncompliance	23,080 (5.0)	15,735 (8.1)	

IQR = interquartile range, SD = Standard deviation, CKD = Chronic Kidney Disease, CAD = Coronary Artery Disease, MI = Myocardial Infarction, TIA= Transient Ischemic Attack

Table 2. Ischemic stroke characteristics and severity in atrial fibrillation patients, stratified by long-term AC use.

	No Anticoagulation n= 460,980 (%)	Long-term Anticoagulation n= 194,560 (%)	P value
Stroke mechanism, n (%)			
Embolic	155,130 (33.7)	59,495 (30.6)	< 0.001
Thrombotic	30,735 (6.7)	10,335 (5.3)	< 0.001
Other/unspecified	275,115 (59.6)	124,730 (64.1)	< 0.001
Vessel occluded, n (%)			
Anterior Cerebral Artery	9,975 (2.2)	3,955 (2.0)	< 0.001
Middle Cerebral Artery	166,055 (36.0)	58,380 (30.0)	< 0.001
Posterior Cerebral Artery	25,000 (5.4)	9,450 (4.9)	< 0.001
Vertebral and Basilar	9,600 (2.1)	3,430 (1.8)	< 0.001
Carotids	23,000 (5.0)	9,500 (4.9)	0.069
Other/ unspecified	219,340 (47.6)	104,640 (53.7)	< 0.001
Small vessel	8,010 (1.7)	5,205 (2.7)	< 0.001
Stroke severity			
Median NIHSS score	7 [2 – 16]	5 [2 – 12]	< 0.001
Mild (NIHSS score 1–4)	70,885 (15.4)	37,955 (19.5)	< 0.001
Moderate (NIHSS score 5–15)	63,685 (13.8)	27,485 (14.1)	< 0.001
Moderate-severe (NIHSS score 16–20)	19,425 (4.2)	6,630 (3.4)	< 0.001
Severe (NIHSS score 21–42)	26,175 (5.7)	8,760 (4.5)	< 0.001

NIHSS = National Institutes of Health Stroke Scale, SNF = Skilled Nursing Facility, ICF = Intermediate Care Facility, LOS = Length of Stay

Table 3. In-hospital mortality and outcomes of atrial fibrillation patients admitted with acute ischemic stroke, stratified by long-term AC use.

	No Anticoagulation n= 460,980 (%)	Long-term Anticoagulation n= 194,560 (%)	Adjusted* OR [95% CI]	P value
Complications, n (%)				
In-hospital Mortality	36,030 (7.8)	9,405 (4.8)	0.62 [0.60 – 0.63]	< 0.001
Intravenous Thrombolysis	76,640 (16.6)	14,260 (7.3)	0.42 [0.41 – 0.43]	< 0.001
Mechanical Thrombectomy	40,835 (8.9)	13,790 (7.1)	0.85 [0.83 – 0.87]	< 0.001
Bleeding complications n (%)				
ICH	42,530 (9.2)	12,455 (6.4)	0.69 [0.67 – 0.71]	< 0.001
GI bleed	9,810 (2.1)	2,895 (1.5)	0.74 [0.70 – 0.77]	< 0.001
All major bleed	59,190 (12.8)	18,530 (9.5)	0.73 [0.71 – 0.74]	< 0.001
Discharge Disposition, n (%)				
Routine	103,525 (22.5)	50,150 (25.8)	1.26 [1.24 – 1.28]	< 0.001
SNF or ICF	232,825 (50.5)	93,575 (48.1)	0.90 [0.89 – 0.91]	< 0.001
Resource utilization, median [IQR]				
Mean LOS, days	4 [3 – 7]	4 [2 – 6]		< 0.001
Mean total charge, USD	\$48,130 [\$27,089 - \$91,45]	\$40,135 [\$24,130 - \$74,378]		< 0.001
*Matching for age, sex, elective admission status, presence of cardiac tamponade, coagulopathy, obesity, hypertension, hypothyroidism, diabetes, CKD, liver disease, lung disease, anemia, congestive heart failure, valvular disease, CAD, peripheral artery disease, atrial fibrillation, smoking, alcohol use, history of stroke/TIA/ MI, and medication non-compliance.				

ICH = Intracranial Hemorrhage, GI = Gastrointestinal. SNF = Skilled Nursing Facility, ICF = Intermediate Care Facility, LOS = Length of Stay

Figure 1. Study flow diagram showing inclusion and exclusion criteria. Hospitalization counts represent national-level estimates.




Figure 2. Forest plot showing crude and adjusted acute ischemic stroke outcomes in patients with atrial fibrillation on long-term anticoagulation versus patients not on long-term anticoagulation. *Adjusted analysis based on age, gender, race, and relevant co-morbidities. *uOR = unadjusted odds ratio; SNF = Skilled Nursing Facility; ICF = Intermediate Care Facility.*

